Fury as train fares could soar by inflation-busting 5.8% next year despite services getting WORSE
It would see the price of a Liverpool-to-Manchester annual flexi ticket jump by £120.30 to £2,195.10.
2
Increases are usually calculated by adding one percentage point to the Retail Price Index figure for inflation — which yesterday hit 4.8 per cent for July.
The RPI is calculated by looking at the prices of 700 products and services but also includes mortgage interest payments and council tax.
Fare rises could see a Woking-to-London season ticket soar by £247 to £4,507.
Meanwhile, punctuality is at its lowest in more than five years.
The Office of Rail and Road found trains reached 66.7 per cent of station stops on time in the year to July 19 — the worst since the year to May 2020.
Labour is nationalising operators as contracts expire, with South Western Railway and c2c now under public ownership.
Ben Plowden of Campaign for Better Transport said: 'The fundamental question for the Government is how to use its role in setting fares policy to deliver a more affordable network and encourage customers.'
Shadow Transport Secretary Richard Holden said: 'Labour's election promises ring hollow as passengers are hit with inflation-busting rises on top of cancelled trains, driver shortages and chaos on the network.'
The Department for Transport said an update on fares will be released later this year.
Peak rail fares scrapped by John Swinney
2
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Thousands await GCSE results across Northern Ireland
Thousands of young people across Northern Ireland are set to receive their GCSE results today. Scores of students will also receive vocational qualification results. Last year around a third of the 32,018 students in the region who received GCSEs results achieved a grade A or better. Last Thursday, more than 25,000 students across the region received their AS and A-level examination results, with 30.4% of entries having achieved the top A* to A grades. Northern Ireland continued to outperform other parts of the UK in the A-level results last week with nearly 86% of pupils in the region receiving an A* to C grade, while the figures for England and Wales were just under 78%. Stormont Economy Minister Caoimhe Archibald has urged students receiving results today and their parents/carers to make use of the advice and guidance offered by her department's Careers Service. 'Making informed decisions following your exam results is crucial in helping you consider the next step on your journey,' she said. 'No matter what your results were, there are many opportunities available to you and I would urge you to examine these fully. 'You may wish to remain at school, or you might want to explore further education courses, start an apprenticeship or training programme or go into employment – my department's Careers Service can provide you with all the help and guidance you need. 'Whatever choice you make, I want to pass on my very best wishes for the future.' Young people and parents can find useful information on the Careers Service website at
Times
2 hours ago
- Times
Is this a good time to buy shares in Convatec?
After a volatile year for shares in Convatec they received a welcome boost on Wednesday when the FTSE 100 medical equipment company launched a share buyback of up to $300 million. The programme, representing up to 5 per cent of Convatec's market capitalisation, will run until the end of the year. The return of surplus capital to shareholders lifted the shares 5.6 per cent, gaining 13p, to close at 244¼p on the London Stock Exchange, the session's biggest riser on the premier share index. The buyback, being handled by UBS, was received by the market as a sign of health in the outlook for Convatec, whose shares, which were up 30 per cent in the first half of the year, have de-rated since June on concerns about product reimbursement cuts in the United States, its largest market, where the Trump administration has launched an efficiency drive. Despite the stock having seemingly priced in the exposure, some investors have remained on the sidelines, concerned that changes to US federal reimbursement in chronic care and skin substitutes could hit Convatec's sales and forecasts more than expected. Convatec has quantified the potential impact. It guided at its half-year results at the end of July for a potential 1 per cent to 2 per cent headwind on its 2026 revenues and the same range in 2027. The company also reiterated its forecasts for the current financial year, of group organic revenue growth of between 5.5 per cent and 7 per cent. This excludes sales of at least $75 million from InnovaMatrix, a wound treatment whose sales are uncertain because of the prospect of a curtailment of Medicare coverage, a US health insurance scheme. Convatec also reiterated an adjusted operating margin between 22 per cent and 22.5 per cent for this year and said it remained on course to 'consistently deliver' medium-term targets of 5 per cent to 7 per cent organic revenue growth and to reach a 'mid-20s' percentage adjusted operating margin by 2026 or 2027. Sellside bulls argue that investors have overlooked Convatec's results. Uncertainty, though, increased this month when Convatec announced, in a brief statement, that Karim Bitar, its well-regarded chief executive, was taking an indefinite medical leave of absence from the company. He has been replaced by Jonny Mason, the chief financial officer, on an interim basis, and Fiona Ryder, the group financial controller, will in turn take Mason's place as chief financial officer in the interim. Since Bitar, 60, was parachuted in as chief executive by Novo Holdings, a top shareholder, in 2019, he has led the turnaround of the FTSE 100 company after a period of profit warnings and boardroom upheaval. Convatec, founded in 1978, employs about 10,000 people globally and operates in around 90 countries. The company's strategy centres on four chronic care categories — including ostomy and continence care — and prioritises 12 key markets, with the United States as its largest. Since 2019 revenue growth has risen from 2.3 per cent; Convatec has delivered six straight years of accelerating growth; its annual research and development expenditure has doubled to about $100 million; and it has replenished its pipeline of new products. Amid the US and leadership uncertainty, then, the share buyback has helped reinforce the bull case. The buyback was consistent with Convatec's capital allocation plans, under which it targets a 2 times net debt/ebitda leverage ratio. Analysts at UBS, Convatec's house broker, forecast a year-end ratio of 1.3 times, rising to 1.7 times following the buyback. The broker, which reiterated its 'buy' rating and 231p price target, believes Convatec has the cashflows for a consistent buyback programme, which excluding mergers and acquisitions, could return up to $2 billion, or one third of Convatec's existing market capitalisation over the next four years. Similarly, Berenberg told clients on Wednesday, before the buyback was announced, that the 20 per cent de-rating in Convatect's shares since June was a 'buying opportunity', with the company trading on a 16 times price-earnings ratio. Advice Buy Why Buyback underpins confident outlook and shares have de-rated since Tempus's recommendation in February
Daily Mail
2 hours ago
- Daily Mail
REVEALED: The forgotten clause that could now force Sir Jim Ratcliffe out of Man United - and what it means for the Glazers, Qataris and new owners
Last Wednesday, Manchester United crept back onto the market. It may well have passed by relatively unnoticed, but August 13 was a technically-significant date for the Premier League giants.
